This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Oncology

Abstral® (Sublingual Fentanyl Tablet)

Abstral® is indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.1

  • INTRODUCTION

    Abstral® is a quick dissolving sublingual tablet formulation of fentanyl. Fentanyl has a rapid onset of analgesia and short duration of action, which makes it suitable to treat episodes of BTcP.1

  • EFFICACY

    Evidence from clinical studies demonstrating Abstral's efficacy in relieving BTcP.

  • PATIENT PREFERENCE

    Placebo formulations of Abstral®, a buccal/sublingual tablet and nasal spray have been compared in a small (n=30) survey to give interesting insight into patient preference.2

  • HOW TO PRESCRIBE

    Guidance on how patients should take Abstral®, including instructions on titration.

  • FORMULATION GUIDANCE

    Information on the need for caution when considering switching transmucosal fentanyl formulations and additional links to further safety considerations.

  • PRESCRIBING INFORMATION

    Direction on prescribing Abstral®.

PecFent® (Fentanyl Pectin Nasal Spray)

PecFent® is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.3

  • INTRODUCTION

    PecFent® is a nasal spray formulation of fentanyl.3 Fentanyl has a rapid onset of analgesia and short duration of action which make it suitable to treat episodes of BTcP.4

  • EFFICACY

    Information on the novel PecSys® nasal drug delivery system, which acts to deliver fentanyl to the nasal mucosa.

  • HOW TO PRESCRIBE

    Information on how to prescribe PecFent®, including titration.

  • SAFETY

    Important safety information, including the need for caution when considering switching transmucosal fentanyl formulations.

  • PRESCRIBING INFORMATION

    Direction on prescribing PecFent®.

SANCUSO® (Granisetron Transdermal Patch)

SANCUSO transdermal patch is indicated for the prevention of nausea and vomiting associated with moderately or highly emetogenic multi-day chemotherapy in adult patients with swallowing difficulties.5

  • INTRODUCTION

    Find out about SANCUSO, the first and only 5-HT3 antagonist patch for the treatment of CINV.5

  • EFFICACY

    Evidence from clinical studies demonstrating the efficacy of SANCUSO in relieving CINV in patients receiving chemotherapy.

  • TOLERABILITY

    Guidance on the most commonly reported side effects and adverse drug reactions.5

  • HOW TO PRESCRIBE

    Guidance on how to prescribe SANCUSO.

  • RESOURCES

    Information and resources for the management of patients who have been prescribed SANCUSO.

  • PRESCRIBING INFORMATION

    Direction on prescribing SANCUSO.

Average:

  • References

    1. Abstral® Summary of Product Characteristics.

    2. England R et al. BMJ Supportive & Palliative Care 2011;1:349-351.

    3. PecFent® Summary of Product Characteristics.

    4. Davies AN et al. BMJ Support Palliative Care 2018;0:1-9. Doi:10.1136/bmjspcare-2017-001467.

    5. SANCUSO 3.1 mg/24 hours transdermal patch SPC.

    KKI/INT/KKI/0605 November 2023